Quick response of advanced cancer to chemoradiation therapy with antineoplastons.
- H Tsuda
- M Sata
- T Kumabe
- H Hara
- N Eriguchi
- Y Sugita
- H Nagamatsu
Affiliations: Department of Anesthesiology, Kurume University, School of Medicine, 67 Asahimachi, Kurumeshi, Fukuokaken, 830, Japan.
- Published online on: May 1, 1998 https://doi.org/10.3892/or.5.3.597
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Antineoplastons A10 and AS2-1 exhibit growth inhibition of cancer cells by diverse modes of action. We observed antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy and antineoplastons A10 and AS2-1 in phase I clinical study being conducted in Kurume University Hospital. We reviewed 3 clinical cases of advanced cancer (multiple metastatic lung cancer, thalamic glioma and primary lung cancer) in which we believed antineoplaston A10 and AS2-1 may be contributing to the rapid antitumor response. The possible use of this combination for induction therapy in advanced cancer is discussed.